118 Hidden Planets, FDA Wearables Risk & CRISPR's $70M Signal
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
118 Hidden Planets, FDA Wearables Risk & CRISPR's $70M Signal
-
ナレーター：
-
著者：
(00:01:03) FDA Wearables Deregulation Risk
(00:01:52) Protein Machinery and Brain Aging
(00:02:31) Kidney Disease 800M Silent Burden
(00:02:59) Vitamins, Fatigue, and Impairment
(00:03:30) CRISPR Funding Signal
An AI pipeline called RAVEN, built at the University of Warwick, has pulled 118 previously undetected planets from NASA's TESS dataset — ultra-short-period worlds and rare Neptunian desert planets that years of human analysis had missed. The story isn't just about exoplanets. It's about a structural shift in how science works: the bottleneck was never the telescope, it was the analysis, and machine learning is closing that gap across astronomy, genomics, and drug discovery simultaneously.
On the medical front, new FDA guidance under the Trump administration reclassifies blood pressure monitoring as a wellness product, letting Oura and Samsung ship wearables without pre-market validation. The speed-to-market gain is real. So is the accuracy risk for the 800 million people worldwide living with chronic kidney disease — many undiagnosed — who depend on reliable readings to manage hypertension.
Stanford researchers using killifish models have pinpointed a precise cellular mechanism: the protein-synthesis machinery inside aging cells deteriorates before the proteins themselves fail, with downstream effects that map to memory loss and neurodegeneration. If the pathway holds in humans, it reframes how Alzheimer's treatment is approached.
Two smaller but trackable findings round out the episode: low B12 and folate linked to persistent fatigue even in otherwise healthy individuals, and a Johns Hopkins study confirming that cannabis edibles combined with alcohol impair driving beyond what standard roadside tests can detect.
Finally, Chinese CRISPR startup YolTech closes a $70 million round ahead of a Hong Kong IPO — the clearest funding signal yet that gene-editing investment is accelerating despite regulatory complexity.
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません